These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32096052)

  • 1. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy.
    Shoji M
    Adv Exp Med Biol; 2019; 1184():393-405. PubMed ID: 32096052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.
    Wagshal D; Sankaranarayanan S; Guss V; Hall T; Berisha F; Lobach I; Karydas A; Voltarelli L; Scherling C; Heuer H; Tartaglia MC; Miller Z; Coppola G; Ahlijanian M; Soares H; Kramer JH; Rabinovici GD; Rosen HJ; Miller BL; Meredith J; Boxer AL
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):244-50. PubMed ID: 24899730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.
    Rosenmann H
    J Mol Neurosci; 2012 May; 47(1):1-14. PubMed ID: 22058061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C.
    de Almeida SM; Ribeiro CE; Rotta I; Piovesan M; Tang B; Vaida F; Raboni SM; Letendre S; Potter M; Batistela Fernandes MS; Ellis RJ;
    J Neurovirol; 2018 Feb; 24(1):28-40. PubMed ID: 29063514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.
    Palmqvist S; Insel PS; Stomrud E; Janelidze S; Zetterberg H; Brix B; Eichenlaub U; Dage JL; Chai X; Blennow K; Mattsson N; Hansson O
    EMBO Mol Med; 2019 Dec; 11(12):e11170. PubMed ID: 31709776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.
    Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S
    Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.
    Meredith JE; Sankaranarayanan S; Guss V; Lanzetti AJ; Berisha F; Neely RJ; Slemmon JR; Portelius E; Zetterberg H; Blennow K; Soares H; Ahlijanian M; Albright CF
    PLoS One; 2013; 8(10):e76523. PubMed ID: 24116116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of immunoprecipitation - two-dimensional liquid chromatography - mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients.
    Bijttebier S; Theunis C; Jahouh F; Martins DR; Verhemeldonck M; Grauwen K; Dillen L; Mercken M
    J Chromatogr A; 2021 Aug; 1651():462299. PubMed ID: 34107398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
    Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
    Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.